CMPS•benzinga•
2 New Studies Look At Compass Pathways' Psilocybin Drug For Anorexia And Depression
Summary
Compass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga